Covid 2 Variants and Vaccines: Review

Maged Naser, Lamia H. Shehata

Abstract


Notwithstanding the rising natural and vaccines mediated immunity, a several nations have encountered a resurgence of the Covid disease of 2019 (Coronavirus) because of the development of severe acute respiratory syndrome Covid 2 (SARS-CoV-2) variations. From Alpha to Omicron, the variants of concern (VOC) have advanced several spike protein changes that might affect infection characteristics, like contagiousness and antigenicity. In this review, we depict the advancement of SARS-CoV-2, sum up current information on epidemiological and clinical highlights of the variants, and talk about the response techniques as far as vaccines to decrease the burden of Coronavirus.


Keywords


Coronavirus, SARS-CoV-2, Spike mutations, Variation of Concern, Vaccines

Full Text:

PDF

References


-Cucinotta, Domenico, and Maurizio Vanelli. "WHO declares COVID-19 a pandemic." Acta bio medica: Atenei parmensis 91.1 (2020): 157.‏

-Candido, Darlan S., et al. "Evolution and epidemic spread of SARS-CoV-2 in Brazil."Science 369.6508 (2020): 1255-1260.‏

-Pereson, Matías J., et al. "Phylogenetic analysis of SARS‐CoV‐2 in the first few months since its emergence." Journal of medical virology 93.3 (2021): 1722-1731.‏

-Minskaia, Ekaterina, et al. "Discovery of an RNA virus 3′→ 5′ exoribonuclease that is critically involved in coronavirus RNA synthesis." Proceedings of the National Academy of Sciences103.13 (2006): 5108-5113.‏

-Korber, Bette, et al. "Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus." Cell 182.4 (2020): 812-827.‏

-Choi, Bina, et al. "Persistence and evolution of SARS-CoV-2 in an immunocompromised host." New England Journal of Medicine 383.23 (2020): 2291-2293.‏

-Avanzato, Victoria A., et al. "Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer." Cell 183.7 (2020): 1901-1912.‏

-Kemp, Steven A., et al. "SARS-CoV-2 evolution during treatment of chronic infection." Nature 592.7853 (2021): 277-282.‏

-Rambaut, Andrew, et al. "Preliminary genomic characterisation of an emergent SARSCoV-2 lineage in the UK defined by a novel set of spike mutations. COVID-19 Genomics Consortium UK (CoG-UK)." (2020).‏

-Tegally, Houriiyah, et al. "Detection of a SARS-CoV-2 variant of concern in South Africa." Nature 592.7854 (2021): 438-443.‏

-Faria, Nuno R., et al. "Genomics and epidemiology of the P. 1 SARS-CoV-2 lineage in Manaus, Brazil." Science 372.6544 (2021): 815-821.‏

-Sabino, Ester C., et al. "Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence." The Lancet 397.10273 (2021): 452-455.‏

-Dhar, Mahesh S., et al. "Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India."Science 374.6570 (2021): 995-999.‏

-Riley, Steven, et al. "REACT-1 round 12 report: resurgence of SARS-CoV-2 infections in England associated with increased frequency of the Delta variant."MedRxiv(2021): 2021-06.

-Tegally, Houriiyah, et al. "Rapid replacement of the Beta variant by the Delta variant in South Africa."MedRxiv(2021): 2021-09.

-Bolze, Alexandre, et al. "SARS-CoV-2 variant Delta rapidly displaced variant Alpha in the United States and led to higher viral loads." Cell Reports Medicine3.3 (2022).‏

-WHO, Tracking SARS. "CoV-2 variants."World Health Organization(2021).

-Walensky, Rochelle P., Henry T. Walke, and Anthony S. Fauci. "SARS-CoV-2 variants of concern in the United States—challenges and opportunities."Jama325.11 (2021): 1037-1038.

-Harvey, William T., et al. "SARS-CoV-2 variants, spike mutations and immune escape."Nature reviews microbiology19.7 (2021): 409-424.‏

-Lazarevic, Ivana, et al. "Immune evasion of SARS-CoV-2 emerging variants: what have we learnt so far?."Viruses13.7 (2021): 1192.‏

-Tao, Kaiming, et al. "The biological and clinical significance of emerging SARS-CoV-2 variants."Nature Reviews Genetics22.12 (2021): 757-773.‏

-Piccoli, Luca, et al. "Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology."Cell183.4 (2020): 1024-1042.‏

-Suryadevara, Naveenchandra, et al. "Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein."Cell184.9 (2021): 2316-2331.‏

-Poh, Chek Meng, et al. "Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients."Nature communications11.1 (2020): 2806.‏

-Greaney, Allison J., et al. "Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies."Cell host & microbe29.3 (2021): 463-476.‏

-McCarthy, Kevin R., et al. "Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape."Science371.6534 (2021): 1139-1142.‏

-Weisblum, Yiska, et al. "Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants."elife9 (2020): e61312.‏

-Liu, Zhuoming, et al. "Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization."Cell host & microbe29.3 (2021): 477-488.‏

-Baum, Alina, et al. "Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies."Science369.6506 (2020): 1014-1018.‏

-Starr, Tyler N., et al. "Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding."cell182.5 (2020): 1295-1310.‏

-Starr, Tyler N., et al. "Prospective mapping of viral mutations that escape antibodies used to treat COVID-19."Science371.6531 (2021): 850-854.‏

-Wang, Pengfei, et al. "Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7."Nature593.7857 (2021): 130-135.‏

-Li, Qianqian, et al. "The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity."Cell182.5 (2020): 1284-1294.‏

-Johnson, Bryan A., et al. "Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis."Nature591.7849 (2021): 293-299.‏

-Meng, Bo, et al. "Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B. 1.1. 7."Cell reports35.13 (2021).‏

-Volz, Erik, et al. "Assessing transmissibility of SARS-CoV-2 lineage B. 1.1. 7 in England."Nature 593.7858 (2021): 266-269.‏

-for Immunization, National Center. "Science Brief: SARS-CoV-2 and Surface (Fomite) Transmission for Indoor Community Environments."CDC COVID-19 Science Briefs [Internet]. Centers for Disease Control and Prevention (US), 2021.

-Lyngse, Frederik Plesner, et al. "Increased transmissibility of SARS-CoV-2 lineage B. 1.1. 7 by age and viral load."Nature Communications12.1 (2021): 7251.‏

-Davies, Nicholas G., et al. "Estimated transmissibility and impact of SARS-CoV-2 lineage B. 1.1. 7 in England."Science372.6538 (2021): eabg3055.‏

-Frampton, Dan, et al. "Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B. 1.1. 7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study."The Lancet infectious diseases21.9 (2021): 1246-1256.‏

-Davies, Nicholas G., et al. "Increased mortality in community-tested cases of SARS-CoV-2 lineage B. 1.1. 7."Nature593.7858 (2021): 270-274.‏

-Challen, Robert, et al. "Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study."bmj372 (2021).‏

-Giles, Benjamin, et al. "The SARS-CoV-2 B. 1.1. 7 variant and increased clinical severity—the jury is out."The Lancet Infectious Diseases21.9 (2021): 1213-1214.‏

-Chen, Xinhua, et al. "Neutralizing Antibodies Against SARS-CoV-2 Variants Induced by Natural Infection or Vaccination: A Systematic Review and Individual Data Meta-Analysis." (2021).‏

-Collier, Dami A., et al. "Sensitivity of SARS-CoV-2 B. 1.1. 7 to mRNA vaccine-elicited antibodies."Nature593.7857 (2021): 136-141.‏

-Emary, Katherine RW, et al. "Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial."The Lancet397.10282 (2021): 1351-1362.‏

-Planas, Delphine, et al. "Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization."Nature596.7871 (2021): 276-280.‏

-Chen, Rita E., et al. "Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies."Nature medicine27.4 (2021): 717-726.‏

-Madhi, Shabir A., et al. "Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant."New England Journal of Medicine384.20 (2021): 1885-1898.‏

-Freitas, André Ricardo Ribas, et al. "The increase in the risk of severity and fatality rate of covid-19 in southern Brazil after the emergence of the Variant of Concern (VOC) SARS-CoV-2 P. 1 was greater among young adults without pre-existing risk conditions."MedRxiv(2021): 2021-04.

-Wang, Pengfei, et al. "Increased resistance of SARS-CoV-2 variant P. 1 to antibody neutralization."Cell host & microbe29.5 (2021): 747-751.‏

-Dejnirattisai, Wanwisa, et al. "Antibody evasion by the P. 1 strain of SARS-CoV-2."Cell184.11 (2021): 2939-2954.‏

-Chen, Kai-Wei K., Daniel Tsung-Ning Huang, and Li-Min Huang. "SARS-CoV-2 variants–evolution, spike protein, and vaccines."biomedical journal45.4 (2022): 573-579.‏

-Luo, Chun Huai, et al. "Infection with the SARS-CoV-2 delta variant is associated with higher infectious virus loads compared to the alpha variant in both unvaccinated and vaccinated individuals."MedRxiv(2021).

-van Kampen, Jeroen JA, et al. "Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)."Nature communications 12.1 (2021): 267.‏

-Liu, Chang, et al. "Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum."Cell184.16 (2021): 4220-4236.‏

-Wall, Emma C., et al. "Neutralising antibody activity against SARS-CoV-2 VOCs B. 1.617. 2 and B. 1.351 by BNT162b2 vaccination."The Lancet397.10292 (2021): 2331-2333.‏

-Sheikh, Aziz, et al. "SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness."The Lancet 397.10293 (2021): 2461-2462.‏

-Jacob, Jobin John, et al. "Evolutionary tracking of SARS-CoV-2 genetic variants highlights an intricate balance of stabilizing and destabilizing mutations."MBio12.4 (2021): 10-1128.

-Mykytyn, Anna Z., et al. "Omicron BA. 1 and BA. 2 are antigenically distinct SARS-CoV-2 variants."BioRxiv(2022): 2022-02.

-Garcia-Beltran, Wilfredo F., et al. "mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant."Cell185.3 (2022): 457-466.‏

-Chen, Jiahui, and Guo-Wei Wei. "Omicron BA. 2 (B. 1.1. 529.2): high potential for becoming the next dominant variant."The journal of physical chemistry letters13.17 (2022): 3840-3849.‏

-Tegally, Houriiyah, et al. "Continued emergence and evolution of Omicron in South Africa: New BA. 4 and BA. 5 lineages."MedRxiv(2022): 2022-05.

-Cao, Yunlong, et al. "Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies."Nature602.7898 (2022): 657-663.‏

-Hachmann, Nicole P., et al. "Neutralization escape by SARS-CoV-2 Omicron subvariants BA. 2.12. 1, BA. 4, and BA. 5."New England Journal of Medicine387.1 (2022): 86-88.‏

-Cao, Yunlong, et al. "BA. 2.12. 1, BA. 4 and BA. 5 escape antibodies elicited by Omicron infection."Nature608.7923 (2022): 593-602.

-Viana, Raquel, et al. "Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa."Nature603.7902 (2022): 679-686.‏

-Yu, Jingyou, et al. "Neutralization of the SARS-CoV-2 Omicron BA. 1 and BA. 2 variants."New England Journal of Medicine386.16 (2022): 1579-1580.‏

-Rössler, Annika, et al. "SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent persons."New England Journal of Medicine386.7 (2022): 698-700.‏

-Planas, Delphine, et al. "Considerable escape of SARS-CoV-2 Omicron to antibody neutralization."Nature602.7898 (2022): 671-675.‏

-Carreño, Juan Manuel, et al. "Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron."Nature602.7898 (2022): 682-688.‏

-Schmidt, Fabian, et al. "Plasma neutralization of the SARS-CoV-2 Omicron variant." New England Journal of Medicine386.6 (2022): 599-601.‏

-Bowen, John E., et al. "Omicron BA. 1 and BA. 2 neutralizing activity elicited by a comprehensive panel of human vaccines."BioRxiv(2022).

-Halford, Florence, et al. "Temporal changes to adult case fatality risk of COVID-19 after vaccination in England between May 2020 and February 2022: a national surveillance study."Journal of the Royal Society of Medicine(2023): 01410768231216332.

-Lyngse, Frederik Plesner, et al. "Transmission of SARS-CoV-2 Omicron VOC subvariants BA. 1 and BA. 2: evidence from Danish households."MedRxiv(2022): 2022-01.

-Rössler, Annika, et al. "Neutralization profile after recovery from SARS-CoV-2 omicron infection."New England Journal of Medicine386.18 (2022): 1764-1766.

-Khan, Khadija, et al. "Omicron sub-lineages BA. 4/BA. 5 escape BA. 1 infection elicited neutralizing immunity."MedRXiv(2022): 2022-04.

-Yamasoba, Daichi, et al. "Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies."The Lancet Infectious Diseases22.7 (2022): 942-943.

-Sheward, Daniel J., et al. "Neutralisation sensitivity of the SARS-CoV-2 omicron (B. 1.1. 529) variant: a cross-sectional study."The Lancet Infectious Diseases22.6 (2022): 813-820.

-Cameroni, Elisabetta, et al. "Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift."Nature602.7898 (2022): 664-670.

-Cathcart, Andrea L., et al. "The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2."biorxiv(2021): 2021-03.

-Goldberg, Yair, et al. "Waning immunity after the BNT162b2 vaccine in Israel."New England Journal of Medicine385.24 (2021): e85.

-Khoury, David S., et al. "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection."Nature medicine27.7 (2021): 1205-1211.

-Chemaitelly, Hiam, et al. "Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar."New England Journal of Medicine385.24 (2021): e83.

-Pouwels, Koen B., et al. "Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK."Nature medicine27.12 (2021): 2127-2135.

-Wang, Zijun, et al. "Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection."Nature595.7867 (2021): 426-431.

-Arbel, Ronen, et al. "BNT162b2 vaccine booster and mortality due to Covid-19." New England Journal of Medicine385.26 (2021): 2413-2420.

-Bar-On, Yinon M., et al. "Protection against Covid-19 by BNT162b2 booster across age groups."New England Journal of Medicine385.26 (2021): 2421-2430.

-Munro, Alasdair PS, et al. "Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial."The Lancet398.10318 (2021): 2258-2276.

-Liu, Xinxue, et al. "Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial."The Lancet398.10303 (2021): 856-869.

-Shaw, Robert H., et al. "Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data."The Lancet397.10289 (2021): 2043-2046.

-Krause, Philip R., et al. "SARS-CoV-2 variants and vaccines."New England Journal of Medicine385.2 (2021): 179-186.

-Wu, Kai, et al. "Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice."Vaccine39.51 (2021): 7394-7400.

-Colson, Philippe, et al. "Culture and identification of a “Deltamicron” SARS‐CoV‐2 in a three cases cluster in southern France."Journal of Medical Virology94.8 (2022): 3739-3749.




DOI: http://dx.doi.org/10.52155/ijpsat.v43.1.6025

Refbacks

  • There are currently no refbacks.


Copyright (c) 2024 Maged Naser

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.